Target intelligence / Profile preview

Immune system reconstitution via allogeneic hematopoietic stem cell engraftment

Molecular classification: Other

Overview

Allogeneic hematopoietic stem cell engraftment is a clinical procedure wherein hematopoietic stem cells from a genetically matched (or partially matched) donor are infused into a recipient after conditioning therapy. The aim is to eradicate a diseased or defective hematopoietic/immune system and allow donor stem cells to repopulate the marrow, restoring normal blood cell and immune system production. This process underlies the curative potential of allogeneic HSCT for a range of malignant, autoimmune, and inherited diseases but is associated with significant risks, including graft-versus-host disease and infections.

Other names: Allogeneic hematopoietic stem cell transplantationAllogeneic HSCTAllogeneic stem cell engraftment

Mechanism of action

Donor stem cell engraftment repopulates recipient marrow and regenerates immune system. Graft-versus-tumor/host responses involve immunologic effects of donor lymphocytes against malignant or host cells. The process also includes the removal of autoreactive or defective immune components via conditioning and cell replacement.

Biological functions

Immune reconstitutionHematopoiesisEradication of defective or malignant hematopoietic/immune systemsImmune tolerance inductionGraft-versus-leukemia/tumor effect

Disease associations

Cancer (leukemia, lymphoma, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms)Autoimmune disease (refractory cases)Inherited metabolic and hematologic disorders (severe combined immunodeficiency, thalassemia, Fanconi anemia, others)Bone marrow failure syndromes

Safety considerations

Graft-versus-host disease (GvHD)Infection (due to immunosuppression)Graft failure (loss of donor-derived hematopoiesis)Relapse of underlying diseaseConditioning-related organ toxicity

Interacting drugs

Chemotherapy and conditioning agents (cyclophosphamide, fludarabine, busulfan, total body irradiation)

2 more in the full profile.

Biomarkers

Chimerism analysis (to monitor engraftment)Absolute neutrophil count and platelet recoveryHLA typing (for donor-recipient compatibility)T cell subset recovery (e.g., CD4/CD8, T regulatory/T conventional ratio)

Beyond the preview

Go deeper on Immune system reconstitution via allogeneic hematopoietic stem cell engraftment.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immune system reconstitution via allogeneic hematopoietic stem cell engraftment.

Explore the full profile